Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 26 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 26 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
25(96.2%)
Phase 2
1(3.8%)
26Total
Phase 1(25)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT02857920Phase 1Completed

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Role: collaborator

NCT02843204Phase 1Completed

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Role: collaborator

NCT03007875Phase 1Completed

High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer

Role: collaborator

NCT03008499Phase 1Completed

High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer

Role: collaborator

NCT02849015Phase 1Completed

Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted Liver

Role: collaborator

NCT02849314Phase 1Completed

Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer

Role: collaborator

NCT02849353Phase 1Completed

Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer

Role: collaborator

NCT02718859Phase 1Completed

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Role: collaborator

NCT02849340Phase 1Completed

Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer

Role: collaborator

NCT02845856Phase 1Completed

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Role: collaborator

NCT02843802Phase 1Completed

Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer

Role: collaborator

NCT02843126Phase 1Completed

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

Role: collaborator

NCT03008304Phase 1Completed

High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer

Role: collaborator

NCT02843815Phase 1Completed

Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT02844335Phase 1Completed

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

Role: collaborator

NCT02849327Phase 1Completed

Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer

Role: collaborator

NCT02843581Phase 1Completed

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

Role: collaborator

NCT02849379Phase 1Completed

Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer

Role: collaborator

NCT02843061Phase 1Completed

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Role: collaborator

NCT02843607Phase 1Completed

Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer

Role: collaborator